UC, MIT Battle Over Patent to Gene-Editing Tool
By Lisa M. Krieger,
San Jose Mercury News
| 05. 09. 2015
Will the University of California reap the financial rewards of CRISPR's commercial use, likely worth billions of dollars? That's the source of a bitter fight.
In June 2012, UC Berkeley's Jennifer Doudna and Emmanuelle Charpentier, now a professor in Germany, showed how bacteria's natural defense system could be turned into a "gene editing" tool to cut DNA strands.
Seven months later, Feng Zhang of the Massachsuetts Institute of Technology, along with Harvard's George Church, showed that the tool also works in human cells.
UC and Doudna filed for a patent first. But in a shocking turn of events, MIT and Zhang won last month, earning the patent that covers use of CRISPR in every species except bacteria, including humans.
MIT paid extra to expedite Zhang's patent application. MIT and Zhang also assert that the patent belongs to them because Doudna didn't prove it works in human cells, only bacterial cells.
Zhang also submitted photos of lab notebooks showing his lab work was ahead of Doudna's.
UC and Doudna are fighting back, submitting thousands of pages of documentation to support their...
Related Articles
By Dr. Coco Newton, Progress Educational Trust | 03.30.2026
Have you ever wondered what it means to have dozens of half-siblings across the world – or to never know where half of your genetic identity comes from? A recent episode of Zembla explores the human consequences of the global...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...
By Alexandre Piquard, Le Monde [cites Katie Hasson] | 04.27.2026
"Si on en prouve la sûreté, nous croyons que l’édition préventive du génome pourrait être l’une des technologies de santé les plus importantes du siècle. » Lucas Harrington explique ainsi le but de son entreprise Preventive : créer des bébés génétiquement modifiés...
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...